PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
17.47
Positive P/E while Medical - Pharmaceuticals median is negative at -0.69. Peter Lynch would investigate competitive advantages in a distressed Medical - Pharmaceuticals.
2.37
P/S less than half the Medical - Pharmaceuticals median of 8.56. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
2.49
P/B 1.1-1.25x Medical - Pharmaceuticals median of 2.06. John Neff would demand superior ROE to justify premium.
55.88
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
55.88
Positive operating cash flow while Medical - Pharmaceuticals median is negative. Peter Lynch would examine operational advantage.
2.49
Fair value ratio 1.1-1.25x Medical - Pharmaceuticals median of 2.10. John Neff would demand superior metrics to justify premium.
1.43%
Positive earnings while Medical - Pharmaceuticals median shows losses. Peter Lynch would examine earnings quality advantage.
1.79%
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash generation advantage.